News In Brief

The long-anticipated merger between pharmaceutical giants SmithKline Beecham and Glaxo Wellcome Plc., both of Britain, more than likely will spawn a new round of takeovers in the industry, analysts said. The companies said they'll combine forces in a deal valued at $182.4 billion. The new company, to be called Glaxo SmithKline, will have about $17.5 billion in annual sales. Together the companies employ 107,000 people, although the merger will result in an unspecified number of layoffs, they said. A spokesman for SmithKline hinted the company may pursue other merger possibilities, and US drugmakers Pfizer and Warner-Lambert also are believed close to a deal.

A buying surge pushed the Nikkei index to a 2-1/2-year high on the Tokyo stock market. The 225-issue indicator closed yesterday's trading at 19,437, its best since Aug. 8, 1997, and was led by shares in Japan's leading brokerage houses and high-tech companies. The 480-point gain followed a 123-point increase last Friday.

(c) Copyright 2000. The Christian Science Publishing Society

About these ads
Sponsored Content by LockerDome

We want to hear, did we miss an angle we should have covered? Should we come back to this topic? Or just give us a rating for this story. We want to hear from you.

Loading...

Loading...

Loading...

Save for later

Save
Cancel

Saved ( of items)

This item has been saved to read later from any device.
Access saved items through your user name at the top of the page.

View Saved Items

OK

Failed to save

You reached the limit of 20 saved items.
Please visit following link to manage you saved items.

View Saved Items

OK

Failed to save

You have already saved this item.

View Saved Items

OK